BR112022019794A2 - Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd) - Google Patents

Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)

Info

Publication number
BR112022019794A2
BR112022019794A2 BR112022019794A BR112022019794A BR112022019794A2 BR 112022019794 A2 BR112022019794 A2 BR 112022019794A2 BR 112022019794 A BR112022019794 A BR 112022019794A BR 112022019794 A BR112022019794 A BR 112022019794A BR 112022019794 A2 BR112022019794 A2 BR 112022019794A2
Authority
BR
Brazil
Prior art keywords
alpha
antytripsin
aatd
dodeca
indazole
Prior art date
Application number
BR112022019794A
Other languages
English (en)
Inventor
Giroux Simon
John Boyd Michael
Francis Fimognari Robert Jr
Zaky Mariam
Lee Grey Ronald Jr
Xu Jinwang
Kesavan Sarathy
Marcel Nuhant Philippe
Manuel Garcia Barrantes Pedro
Jones Peter
Aaron Brodney Michael
Marie Boucher Diane
T D Fanning Lev
B Hall Amy
James Hurley Dennis
Patrick Maxwell John
Arthur Johnson Mac Jr
Lewis Tapley Timothy
Jane Swett Rebecca
Damagnez Veronique
A Thomson Stephen
Michael Cottrell Kevin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR112022019794A2 publication Critical patent/BR112022019794A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

DERIVADOS DE PIRROLO[2,3-F]INDAZOL E 2,4,5,10-TETRAZATRICICLO[7.3.0.03,7]DODECA-1,3(7),5,8,11- PENTENO COMO MODULADORES DA ALFA-1-ANTITRIPSINA PARA TRATAMENTO DA DEFICIÊNCIA DE ALFA-1-ANTITRIPSINA (AATD). Derivados de pirrolo[2,3-f]indazol e 2,4,5,10- tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-penteno como moduladores da alfa-1 antripsina para tratamento da deficiência de alfa-1 antitripsina (AATD).
BR112022019794A 2020-04-03 2021-04-02 Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd) BR112022019794A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004636P 2020-04-03 2020-04-03
PCT/US2021/025597 WO2021203010A1 (en) 2020-04-03 2021-04-02 Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd)

Publications (1)

Publication Number Publication Date
BR112022019794A2 true BR112022019794A2 (pt) 2022-12-06

Family

ID=75690656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019794A BR112022019794A2 (pt) 2020-04-03 2021-04-02 Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)

Country Status (13)

Country Link
US (1) US20230159580A1 (pt)
EP (1) EP4126877A1 (pt)
JP (1) JP2023520398A (pt)
KR (1) KR20220163429A (pt)
CN (1) CN115776984A (pt)
AR (1) AR121744A1 (pt)
AU (1) AU2021247282A1 (pt)
BR (1) BR112022019794A2 (pt)
CA (1) CA3179184A1 (pt)
IL (1) IL296750A (pt)
MX (1) MX2022012095A (pt)
TW (1) TW202204359A (pt)
WO (1) WO2021203010A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
CN116813623A (zh) * 2022-03-21 2023-09-29 东南大学 一种吡咯并[2,3-f]吲唑类化合物的制备方法
PE20251573A1 (es) 2022-09-09 2025-06-12 Vertex Pharma Moduladores de la alfa-1 antitripsina
WO2025236095A1 (en) * 2024-05-17 2025-11-20 Congruence Therapeutics Inc. Modulators of alpha-1 antitrypsin
WO2026014456A1 (ja) * 2024-07-10 2026-01-15 株式会社アークメディスン 化合物、補体ｄ因子阻害剤、及び医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013853A (es) * 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
CA3114672A1 (en) * 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) * 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—１抗胰蛋白酶缺乏症之治療方法

Also Published As

Publication number Publication date
US20230159580A1 (en) 2023-05-25
WO2021203010A1 (en) 2021-10-07
AR121744A1 (es) 2022-07-06
CN115776984A (zh) 2023-03-10
MX2022012095A (es) 2023-01-11
AU2021247282A1 (en) 2022-10-27
IL296750A (en) 2022-11-01
CA3179184A1 (en) 2021-10-07
EP4126877A1 (en) 2023-02-08
TW202204359A (zh) 2022-02-01
JP2023520398A (ja) 2023-05-17
KR20220163429A (ko) 2022-12-09

Similar Documents

Publication Publication Date Title
BR112022019794A2 (pt) Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd)
EP4360713A3 (en) Quinazoline derivatives as antitumor agents
UY38696A (es) Moduladores de alfa-1 antitripsina
UY38403A (es) Moduladores de la alfa-1 antitripsina
MX2025002953A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
WO2019209962A8 (en) Compounds and uses thereof
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
WO2019209948A8 (en) Compounds and uses thereof
MX2024006768A (es) Compuestos y usos de los mismos.
EP4603148A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
MX2025003515A (es) Moduladores de akt1
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
DOP2025000055A (es) Moduladores de la alfa-1 antitripsina
WO2022214869A3 (en) 2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
WO2019236765A8 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
MX2023005589A (es) Formas sólidas de ácido 4-(5-(4-fluorofenil)-6-(tetrahidro-2h-pira n-4-il)-1,5-dihidropirrolo[2,3-f]indazol-7-il)benzoico.
WO2023183613A3 (en) Indolizine compounds for the treatment of mental disorders or inflammation
MX2025002176A (es) Inhibidores de tyk2 y usos de los mismos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements